These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8522478)

  • 21. Stability of doripenem, imipenem and meropenem at elevated room temperatures.
    Keel RA; Sutherland CA; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Feb; 37(2):184-5. PubMed ID: 20702066
    [No Abstract]   [Full Text] [Related]  

  • 22. Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
    Matsumoto T; Kumazawa J; Nagayama A
    J Antimicrob Chemother; 1996 Aug; 38(2):322-4. PubMed ID: 8877553
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Enterobacteriaceae, Pseudomonas and Acinetobacter in Southern Poland.
    Drzewiecki A; Bulanda M; Talaga K; Sodo A; Adamski P
    Pol Przegl Chir; 2012 Sep; 84(9):449-53. PubMed ID: 23241660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing.
    Tenover FC; Kalsi RK; Williams PP; Carey RB; Stocker S; Lonsway D; Rasheed JK; Biddle JW; McGowan JE; Hanna B
    Emerg Infect Dis; 2006 Aug; 12(8):1209-13. PubMed ID: 16965699
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a meropenem susceptibility disc: drug content, preliminary interpretive and quality control criteria and potency bioassay.
    Pitkin DH; Sheikh W; Nadler H
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():251-8. PubMed ID: 2808211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic profiling of doripenem, imipenem and meropenem against prevalent Gram-negative organisms in the Asia-Pacific region.
    Kiratisin P; Keel RA; Nicolau DP
    Int J Antimicrob Agents; 2013 Jan; 41(1):47-51. PubMed ID: 23127484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential factors influencing carbapenem activity against Bacteroides fragilis group isolates.
    Iaconis JP; Nadler HL; Sheikh W
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S361-3. PubMed ID: 7548598
    [No Abstract]   [Full Text] [Related]  

  • 28. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates.
    Wexler HM; Engel AE; Glass D; Li C
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4413-7. PubMed ID: 16189137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K; Ishida A; Chinzei T
    Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro antibacterial activity of S-4661, a new parenteral carbapenem, against urological pathogens isolated from patients with complicated urinary tract infections.
    Nomura S; Nagayama A
    J Chemother; 2002 Apr; 14(2):155-60. PubMed ID: 12017370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of disk diffusion test for carbapenem sensitivity in Acinetobacter baumannii and Pseudomonas aeruginosa strains].
    Akan OA; Uysal S
    Mikrobiyol Bul; 2005 Jul; 39(3):273-9. PubMed ID: 16358486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumococcal susceptibility to meropenem.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1996 May; 37(5):1036-7. PubMed ID: 8737158
    [No Abstract]   [Full Text] [Related]  

  • 34. Meropenem and imipenem activity against Pseudomonas aeruginosa isolates from the MYSTIC Program.
    Turner PJ
    Diagn Microbiol Infect Dis; 2006 Nov; 56(3):341-4. PubMed ID: 17049798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
    Kitzis MD; Acar JF; Gutmann L
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():125-32. PubMed ID: 2808204
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of imipenem and meropenem antibiotics for the MALDI-TOF MS detection of carbapenemase activity.
    Rotova V; Papagiannitsis CC; Skalova A; Chudejova K; Hrabak J
    J Microbiol Methods; 2017 Jun; 137():30-33. PubMed ID: 28390706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discordant carbapenem susceptibility in Methylobacterium species and its application as a method for phenotypic identification.
    Zaharatos GJ; Dascal A; Miller MA
    J Clin Microbiol; 2001 May; 39(5):2037-8. PubMed ID: 11388170
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging resistance to carbapenems in a tertiary care hospital in north India.
    Gupta E; Mohanty S; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2006 Jul; 124(1):95-8. PubMed ID: 16926463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of doripenem against Acinetobacter baumannii clinical isolates.
    Marti S; Sánchez-Céspedes J; Alba V; Vila J
    Int J Antimicrob Agents; 2009 Feb; 33(2):181-2. PubMed ID: 18977642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.